Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as… Read more
Active Biotech AB (ACTI) - Net Assets
Latest net assets as of September 2025: Skr4.50 Million SEK
Based on the latest financial reports, Active Biotech AB (ACTI) has net assets worth Skr4.50 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr17.00 Million) and total liabilities (Skr12.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr4.50 Million |
| % of Total Assets | 26.47% |
| Annual Growth Rate | -11.76% |
| 5-Year Change | 45.03% |
| 10-Year Change | -82.24% |
| Growth Volatility | 68.29 |
Active Biotech AB - Net Assets Trend (2000–2024)
This chart illustrates how Active Biotech AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Active Biotech AB (2000–2024)
The table below shows the annual net assets of Active Biotech AB from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr32.07 Million | +4.57% |
| 2023-12-31 | Skr30.67 Million | -11.14% |
| 2022-12-31 | Skr34.51 Million | -26.06% |
| 2021-12-31 | Skr46.67 Million | +111.07% |
| 2020-12-31 | Skr22.11 Million | -58.88% |
| 2019-12-31 | Skr53.78 Million | -38.82% |
| 2018-12-31 | Skr87.92 Million | +13.18% |
| 2017-12-31 | Skr77.68 Million | -57.45% |
| 2016-12-31 | Skr182.56 Million | +1.08% |
| 2015-12-31 | Skr180.60 Million | -55.44% |
| 2014-12-31 | Skr405.31 Million | -0.03% |
| 2013-12-31 | Skr405.41 Million | +19.27% |
| 2012-12-31 | Skr339.92 Million | -32.29% |
| 2011-12-31 | Skr501.99 Million | +176.19% |
| 2010-12-31 | Skr181.76 Million | -3.65% |
| 2009-12-31 | Skr188.64 Million | +15.30% |
| 2008-12-31 | Skr163.61 Million | -13.69% |
| 2007-12-31 | Skr189.57 Million | +214.08% |
| 2006-12-31 | Skr60.36 Million | -65.86% |
| 2005-12-31 | Skr176.81 Million | +8.94% |
| 2004-12-31 | Skr162.30 Million | -43.95% |
| 2003-12-31 | Skr289.58 Million | -23.85% |
| 2002-12-31 | Skr380.27 Million | -43.98% |
| 2001-12-31 | Skr678.78 Million | +5.07% |
| 2000-12-31 | Skr646.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Active Biotech AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5586.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr6.35 Million | 19.81% |
| Other Components | Skr3.51 Billion | 10940.01% |
| Total Equity | Skr32.07 Million | 100.00% |
Active Biotech AB Competitors by Market Cap
The table below lists competitors of Active Biotech AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Youxin Technology Ltd Class A Ordinary shares
NASDAQ:YAAS
|
$3.42 Million |
|
KNM Group Bhd
KLSE:7164
|
$3.43 Million |
|
E Investment & Development
KO:093230
|
$3.43 Million |
|
Fremont Gold Ltd
OTCQB:FRERF
|
$3.43 Million |
|
Sekur Private Data Ltd
OTCQX:SWISF
|
$3.42 Million |
|
Posera Ltd
OTCQB:PRRSF
|
$3.42 Million |
|
BTU Metals Corp
OTCQB:BTUMF
|
$3.42 Million |
|
Hoffmen Cleanindo
JK:KING
|
$3.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Active Biotech AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 30,667,000 to 32,070,000, a change of 1,403,000 (4.6%).
- Net loss of 39,400,000 reduced equity.
- Share repurchases of 33,229,000 reduced equity.
- New share issuances of 33,200,000 increased equity.
- Other factors increased equity by 40,832,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-39.40 Million | -122.86% |
| Share Repurchases | Skr33.23 Million | -103.61% |
| Share Issuances | Skr33.20 Million | +103.52% |
| Other Changes | Skr40.83 Million | +127.32% |
| Total Change | Skr- | 4.57% |
Book Value vs Market Value Analysis
This analysis compares Active Biotech AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.53x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.53x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | Skr13.68 | Skr0.04 | x |
| 2003-12-31 | Skr5.11 | Skr0.04 | x |
| 2004-12-31 | Skr2.21 | Skr0.04 | x |
| 2005-12-31 | Skr2.08 | Skr0.04 | x |
| 2006-12-31 | Skr0.68 | Skr0.04 | x |
| 2007-12-31 | Skr1.99 | Skr0.04 | x |
| 2008-12-31 | Skr1.85 | Skr0.04 | x |
| 2009-12-31 | Skr1.81 | Skr0.04 | x |
| 2010-12-31 | Skr1.56 | Skr0.04 | x |
| 2011-12-31 | Skr4.11 | Skr0.04 | x |
| 2012-12-31 | Skr2.77 | Skr0.04 | x |
| 2013-12-31 | Skr3.02 | Skr0.04 | x |
| 2014-12-31 | Skr2.97 | Skr0.04 | x |
| 2015-12-31 | Skr1.20 | Skr0.04 | x |
| 2016-12-31 | Skr1.21 | Skr0.04 | x |
| 2017-12-31 | Skr0.51 | Skr0.04 | x |
| 2018-12-31 | Skr0.52 | Skr0.04 | x |
| 2019-12-31 | Skr0.27 | Skr0.04 | x |
| 2020-12-31 | Skr0.13 | Skr0.04 | x |
| 2021-12-31 | Skr0.19 | Skr0.04 | x |
| 2022-12-31 | Skr0.13 | Skr0.04 | x |
| 2023-12-31 | Skr0.11 | Skr0.04 | x |
| 2024-12-31 | Skr0.08 | Skr0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Active Biotech AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -122.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.35x
- Recent ROE (-122.86%) is below the historical average (-96.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 4.86% | 32.29% | 0.14x | 1.10x | Skr-34.86 Million |
| 2002 | -78.60% | 0.00% | -0.01x | 1.23x | Skr-336.92 Million |
| 2003 | -106.22% | -91820.60% | 0.00x | 1.19x | Skr-336.56 Million |
| 2004 | -107.35% | -249.88% | 0.22x | 1.93x | Skr-190.46 Million |
| 2005 | -76.59% | -1479.62% | 0.02x | 3.21x | Skr-153.10 Million |
| 2006 | -230.59% | -209.74% | 0.14x | 7.66x | Skr-145.22 Million |
| 2007 | -109.57% | -1719.95% | 0.02x | 2.58x | Skr-226.68 Million |
| 2008 | -110.99% | -339.69% | 0.11x | 2.89x | Skr-197.95 Million |
| 2009 | -118.73% | -2079.25% | 0.02x | 2.64x | Skr-242.84 Million |
| 2010 | -121.63% | -1946.68% | 0.02x | 2.77x | Skr-239.24 Million |
| 2011 | -18.84% | -40.30% | 0.27x | 1.71x | Skr-144.75 Million |
| 2012 | -51.49% | -79.88% | 0.31x | 2.05x | Skr-209.01 Million |
| 2013 | -52.31% | -196.11% | 0.14x | 1.89x | Skr-252.63 Million |
| 2014 | -57.12% | -10221.28% | 0.00x | 1.78x | Skr-272.04 Million |
| 2015 | -107.16% | -1189.13% | 0.04x | 2.49x | Skr-211.59 Million |
| 2016 | -32.64% | -312.91% | 0.05x | 2.26x | Skr-77.84 Million |
| 2017 | -140.06% | -537.36% | 0.07x | 3.91x | Skr-116.56 Million |
| 2018 | -41.95% | -183.92% | 0.07x | 3.44x | Skr-45.67 Million |
| 2019 | -67.06% | -428.08% | 0.13x | 1.24x | Skr-41.44 Million |
| 2020 | -145.24% | -477.58% | 0.21x | 1.45x | Skr-34.33 Million |
| 2021 | -106.88% | -801.33% | 0.11x | 1.22x | Skr-54.55 Million |
| 2022 | -170.06% | 0.00% | 0.00x | 1.48x | Skr-62.14 Million |
| 2023 | -149.35% | 0.00% | 0.00x | 1.44x | Skr-48.87 Million |
| 2024 | -122.86% | 0.00% | 0.00x | 1.35x | Skr-42.61 Million |
Industry Comparison
This section compares Active Biotech AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $47,034,864
- Average return on equity (ROE) among peers: -125.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Active Biotech AB (ACTI) | Skr4.50 Million | 4.86% | 2.78x | $3.42 Million |
| 2cureX AB (2CUREX) | $43.03 Million | -69.18% | 0.11x | $1.39 Million |
| Abliva AB (ABLI) | $70.72 Million | -135.06% | 0.24x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $25.35 Million |
| AcouSort AB (ACOU) | $33.02 Million | -37.49% | 0.11x | $4.79 Million |
| Alzinova AB (ALZ) | $59.11 Million | -10.49% | 0.07x | $3.99 Million |
| AlzeCure Pharma (ALZCUR) | $32.97 Million | -235.89% | 0.38x | $12.21 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $4.76 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $757.29K |
| Biosergen AS (BIOSGN) | $22.79 Million | -149.37% | 0.48x | $2.84 Million |